Clinical benefit of cancer drugs approved in Switzerland 2010-2019.

Publikation

Clinical benefit of cancer drugs approved in Switzerland 2010-2019.

Wissenschaftlicher Artikel/Review - 10.06.2022

Adam Roman, Tibau Ariadna, Molto Valiente Consolación, Seruga Bostjan, Ocana Alberto, Amir Eitan, Templeton Arnoud J

Zitation

Adam R, Tibau A, Molto Valiente C, Seruga B, Ocana A, Amir E, Templeton A. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PloS one 2022; 17:e0268545.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

PloS one 2022; 17

Veröffentlichungsdatum

10.06.2022

eISSN (Online)

1932-6203

Seiten

e0268545

Kurzbeschreibung/Zielsetzung

It is unknown to what extent cancer drugs approved in Switzerland by the Swissmedic fulfil criteria of clinical benefit according to the European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS), the American Society of Clinical Oncology Value Framework version 2 (ASCO-VF) and the Swiss OLUtool v2 (OLUtool).